Clear cell sarcoma shows immunoreactivity for microphthalmia transcription factor: Further evidence for melanocytic differentiation

69Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

Microphthalmia transcription factor, a melanocytic nuclear protein critical for the embryonic development and postnatal viability of melanocytes, is a master regulator in modulating extracellular signals. Recently, microphthalmia transcription factor expression was shown to be both a sensitive and specific marker of epithelioid melanoma. We investigated the sensitivity of D5, an anti-microphthalmia transcription factor antibody, for diagnosis of clear cell sarcoma (also known as malignant melanoma of soft parts). Immunoreactivity in a nuclear pattern for D5 was present in 8 of 12 (75%) tumors. D5 staining was strong in three tumors, moderate in two, and weak in three. S-100 protein expression was seen in all 12 cases that had clear cell sarcoma examined. HMB-45 staining was seen in 11 of 12 (92%) tumors. Focal Melan-A positivity was seen in 3 of 7 (43%) tumors. Although D5 was shown in a previous study to be a highly sensitive and specific marker for epithelioid melanomas, the results of this study expand the spectrum of tumors showing immunoreactivity for D5. D5 immunoreactivity in clear cell sarcoma provides further evidence for melanocytic differentiation in this unusual tumor.

Cite

CITATION STYLE

APA

Granter, S. R., Weilbaecher, K. N., Quigley, C., Fletcher, C. D. M., & Fisher, D. E. (2001). Clear cell sarcoma shows immunoreactivity for microphthalmia transcription factor: Further evidence for melanocytic differentiation. Modern Pathology, 14(1), 6–9. https://doi.org/10.1038/modpathol.3880249

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free